ARA290
ARA-290
A synthetic 11-amino-acid peptide with the sequence of a solvent-exposed face of helix B of erythropoietin. It does not bind the erythropoietin receptor that drives red-cell production; the published work describes activity at the heteromeric receptor formed by the erythropoietin receptor and the common beta receptor CD131.
ARA-290 has 3 registered human studies on ClinicalTrials.gov, reaching phase 2, covering 97 planned or enrolled participants across the 3 studies that published a figure. No FDA-approved product contains ARA-290. 8 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names ARA-290; the registry search is fuzzy, so every match is re-checked. None of this says whether ARA-290 works or is safe.
FDA status
Research only
Human studies
3
Furthest phase
Phase 2
Papers, 10 yr
8
Readership
—
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Phase 1 or 2 only
3
Registered human studies
Phase 2
Furthest phase reached
97
Planned or enrolled participants, across 3 studies that published a figure
None
No FDA-approved product contains it
4 loose registry matches were checked and 3 confirmed — 1 named something else and were discarded. We count a study only when ARA-290 is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What ARA-290 is, and what it has been studied for
ARA-290 is classified by ChEMBL as a protein.
Across 3 registered trials, it has been studied in Diabetic Macular Oedema, Diabetes Type 2, Impaired Glucose Tolerance and Impaired Fasting Glucose. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Belfast Health and Social Care Trust and Claes-Göran Östenson among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
ARA-290 reached Phase 2 across 3 registered trials.
No FDA-approved product contains ARA-290. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying ARA-290?
Papers published each year that name ARA-290 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 2 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 2 | 0 | Yes |
| 2021 | 2 | 0 | Yes |
| 2022 | 2 | 0 | Yes |
| 2023 | 1 | 0 | Yes |
| 2024 | 0 | 0 | Yes |
| 2025 | 0 | 0 | Yes |
| 2026 | 1 | 0 | No |
8 papers between 2017 and 2026. A paper counts when “ARA 290” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on ARA-290
8 indexed papers name ARA-290 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis
- ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
- A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
- Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region
- ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
Collected 2026-08-02from PubMed, phrase-matched on “ARA 290” in title and abstract. Run the same search.
About ARA-290
A synthetic 11-amino-acid peptide with the sequence of a solvent-exposed face of helix B of erythropoietin. It does not bind the erythropoietin receptor that drives red-cell production; the published work describes activity at the heteromeric receptor formed by the erythropoietin receptor and the common beta receptor CD131.
- Also known as
- Cibinetide · Helix B surface peptide · pHBSP
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.